Participate in the Class Action Against MoonLake Immunotherapeutics before the Deadline

Join the Class Action Against MoonLake Immunotherapeutics

Investors in MoonLake Immunotherapeutics (NASDAQ: MLTX) are being encouraged to take action as a class action lawsuit prepares to challenge the company’s business practices. The Gross Law Firm, a well-respected firm known for its advocacy on behalf of shareholders, has issued a notice emphasizing that those who purchased shares during the specified class period should register to participate. This is an opportunity for investors affected by potentially misleading practices to seek justice and compensation.

The deadline to participate in this action is December 15, 2025, and it’s crucial that shareholders act quickly. Investors who acquired shares of MLTX between March 10, 2024, and September 29, 2025, should strongly consider getting involved in this class action, as their participation may lead to significant recovery for losses incurred during that period.

Allegations Against MoonLake Immunotherapeutics

The allegations brought forward within the lawsuit center on the assertion that MoonLake Immunotherapeutics misled investors by making false claims regarding its drug candidate, SLK. Specifically, the complaint states that the company failed to disclose crucial information related to its drug’s efficacy and its similarity to an already available treatment, BIMZELX.

1. Shared Molecular Targets: The lawsuit claims that both SLK and BIMZELX target the same inflammatory cytokines (IL-17A and IL-17F), which questions the uniqueness and potential clinical benefit of SLK.
2. Clinical Benefit Doubts: The distinct Nanobody structure of SLK, touted as a superior alternative, allegedly does not provide significant clinical advantages over the traditional monoclonal antibody structure of BIMZELX.
3. Efficacy Concerns: Additionally, the complaint questions whether the supposed enhanced tissue penetration of SLK converts to actual clinical effectiveness.
4. Inverted Assumptions: Based on these points, the firm argues that the defendants behind MoonLake Immunotherapeutics lacked valid grounds for their optimistic statements regarding SLK compared to existing treatments.

Next Steps for Interested Shareholders

For those interested in joining the lawsuit, the process is straightforward. By registering on the Gross Law Firm's website, shareholders will not only allow their voices to be heard but also receive ongoing updates about the case through monitoring software designed to keep them in the loop.

There is no cost to participate, and doing so may afford shareholders the opportunity to reclaim some of their losses if the lawsuit results in a favorable outcome. Potential lead plaintiffs are specifically encouraged to come forward before the deadline, emphasizing the importance of swift action.

Why Choose The Gross Law Firm?

The Gross Law Firm is recognized nationally as a leader in class action litigation, dedicated to safeguarding the rights of investors. Their commitment to ensuring corporate accountability and ethical business practices drives their pursuit of recovery for individuals affected by alleged fraud. The firm aims to protect investors from deceitful practices that have led to financial losses, emphasizing that participation in this legal action holds no financial obligation for affected shareholders. Each potential lead plaintiff will have the unique opportunity to take a stand against corporate misconduct, channeling the efforts towards restoring investor confidence.

Conclusion

If you purchased shares of MoonLake Immunotherapeutics during the specified class period, now is the time to act. Make sure you register before the December 15, 2025 deadline and position yourself to possibly reclaim any losses sustained during this tumultuous time for shareholders. To get started, visit The Gross Law Firm's website and complete the necessary registration form. Your participation could be vital in holding corporations accountable for their actions.